Drug Interactions

Psilocybin Drug Interactions

Understanding drug interactions is essential harm reduction for anyone considering psilocybin. This page covers the most clinically significant interactions — what is known, what is uncertain, and what the practical guidance is for each category.

This information is based on the pharmacological literature, clinical trial protocols, and harm reduction research. It is not a substitute for medical advice. Disclose all medications and supplements to your facilitator before any session.

How Psilocybin Works — The Interaction Basis

Psilocybin is converted in the body to psilocin, which acts primarily as a 5-HT2A serotonin receptor agonist. It also has activity at 5-HT2C, 5-HT1A, and several other receptor subtypes. Most clinically significant drug interactions occur through:

1. Serotonergic mechanisms — combining psilocybin with other serotonergic drugs can produce additive effects ranging from blunted response to serotonin toxicity
2. Metabolic interactions — drugs that inhibit or induce CYP2D6 (psilocybin's primary metabolic enzyme) can alter duration and intensity
3. Pharmacodynamic interactions — drugs that affect the same receptor systems or downstream pathways can add to, reduce, or unpredictably modify effects

Hard Contraindications

MAOIs (Monoamine Oxidase Inhibitors)

Risk: Severe — Do not combine

MAOIs inhibit the enzymes that break down monoamines including serotonin. Combined with psilocybin, this can dramatically potentiate effects (2–5× intensity, extended duration) and — at sufficient doses — produce serotonin toxicity.

MAOIs include:

• Phenelzine (Nardil)
• Tranylcypromine (Parnate)
• Isocarboxazid (Marplan)
• Selegiline (Emsam) — at high doses
• Moclobemide (Manerix) — reversible MAOI, lower risk but still significant

Washout period required: Traditional (irreversible) MAOIs require a 14-day washout before psilocybin. Moclobemide requires 24–48 hours minimum. Do not proceed without confirming full washout with a physician.

Lithium

Risk: Severe — Do not combine

Lithium combined with psychedelics has been associated with seizures in case reports. The mechanism is not fully understood. This interaction applies to psilocybin as well as other classical psychedelics.

People on lithium who want to pursue psilocybin therapy must taper and discontinue lithium under psychiatric supervision, with adequate washout time, before any session. Do not attempt lithium tapering without psychiatric guidance.

Significant Interactions — Use With Caution

SSRIs (Selective Serotonin Reuptake Inhibitors)

Risk: Effects blunted or eliminated; possible mild serotonin effects

This is the most common interaction, given that approximately 13% of Americans take antidepressants. Chronic SSRI use downregulates 5-HT2A receptors — psilocybin's primary target — significantly blunting or in some cases completely eliminating the subjective and therapeutic effects.

SSRIs include: fluoxetine (Prozac), sertraline (Zoloft), escitalopram (Lexapro), citalopram (Celexa), paroxetine (Paxil), fluvoxamine (Luvox).

Practical guidance:

• Many people on SSRIs report little to no effect from standard psilocybin doses
• Abruptly stopping SSRIs to restore psilocybin sensitivity is dangerous — discontinuation syndrome (brain zaps, dizziness, emotional instability) and rebound depression are real risks
• Taper SSRIs only under physician guidance with a clear medical rationale
• Some people taper, wait for 5–7 half-lives of clearance, then proceed; others choose to try psilocybin while on SSRIs (accepting reduced effect) rather than discontinue
• Fluoxetine has the longest half-life (up to 6 weeks for full clearance including active metabolites) — plan washout accordingly

SNRIs (Serotonin-Norepinephrine Reuptake Inhibitors)

Risk: Similar to SSRIs — blunted effects

SNRIs (venlafaxine/Effexor, duloxetine/Cymbalta, desvenlafaxine/Pristiq) have similar blunting effects to SSRIs via 5-HT2A downregulation. The same washout and taper guidance applies.

Tramadol

Risk: Serotonin syndrome

Tramadol has serotonergic activity in addition to its opioid effects. Combined with psilocybin, it carries a meaningful risk of serotonin syndrome — a potentially life-threatening condition characterized by hyperthermia, agitation, clonus, and autonomic instability. Avoid this combination.

Antipsychotics (Typical and Atypical)

Risk: Effects blunted; unpredictable interaction

Typical antipsychotics (haloperidol, chlorpromazine) act as 5-HT2A antagonists and will significantly blunt or block psilocybin's effects. Atypical antipsychotics (quetiapine/Seroquel, risperidone, olanzapine) have variable 5-HT2A affinity and unpredictable interactions.

From a harm reduction standpoint, antipsychotics can be used to abort a psilocybin experience if necessary. From a therapeutic standpoint, they make psilocybin therapy unlikely to be effective.

Tricyclic Antidepressants (TCAs)

Risk: Effects blunted; cardiac considerations

TCAs (amitriptyline, nortriptyline, clomipramine) have serotonergic and antihistamine activity that partially blunts psilocybin effects. Some TCAs also have cardiac effects — combined with psilocybin's transient cardiovascular effects, this warrants medical evaluation.

St. John's Wort

Risk: Potential serotonin effects; CYP induction

St. John's Wort is a CYP3A4 and CYP2D6 inducer that can alter psilocybin metabolism. It also has serotonergic activity. Discontinue at least two weeks before a psilocybin session.

Moderate Interactions — Inform Your Facilitator

Beta Blockers

Effect: Mild reduction in cardiovascular and anxiety response

Beta blockers (propranolol, atenolol, metoprolol) reduce the cardiovascular effects of psilocybin (blood pressure and heart rate elevation) and may modestly reduce anxiety. Some researchers believe they mildly blunt the overall experience. Generally considered safe to continue, but disclose to your facilitator.

Benzodiazepines

Effect: Reduces intensity; can abort experience

Benzodiazepines (diazepam, lorazepam, alprazolam, clonazepam) reduce the intensity of a psilocybin experience and can abort it within 20–30 minutes if needed. This makes them a useful harm reduction tool in emergency situations — but they should not be used simply to reduce anxiety at the start of a session, as this significantly impairs therapeutic potential.

People on chronic benzodiazepine therapy may experience modestly blunted psilocybin effects. Acute use of benzodiazepines to manage anticipatory anxiety before a session is counterproductive and not recommended.

Blood Pressure Medications

Effect: Interaction with transient BP elevation

Psilocybin causes transient blood pressure elevation. People on antihypertensive medications should disclose this to their facilitator and, if blood pressure is a significant concern, to a physician before proceeding.

Stimulants (Adderall, Ritalin, Modafinil)

Effect: May increase anxiety and cardiovascular load

Stimulants increase heart rate and blood pressure, which compounds psilocybin's similar effects. They may also increase anxiety and hypervigilance during the session. Avoid stimulants on the day of a session; discuss regular stimulant use with your facilitator.

Substances to Avoid on Session Day

Cannabis (THC)

THC dramatically intensifies psilocybin effects and significantly increases the risk of anxiety and paranoia. Many difficult experiences involve cannabis combined with psilocybin. Avoid cannabis for at least 24 hours before a session. If you use cannabis during a session, expect a substantially more intense and potentially more chaotic experience.

CBD without THC has minimal interaction and is generally considered safe.

Alcohol

Alcohol is a CNS depressant that blunts psilocybin effects and impairs emotional processing. It also impairs the next-day integration window. Avoid for 24 hours before and avoid entirely on session day.

Other Psychedelics

Combining psilocybin with LSD, DMT, mescaline, or other classical psychedelics produces additive or super-additive effects. This is not recommended outside of very specific harm reduction contexts. The duration and intensity become very difficult to predict.

Substances With Minimal Known Interaction

• Caffeine: Moderate caffeine use has minimal known interaction, though high doses may increase anxiety onset.
• Melatonin: No known significant interaction.
• Most antihistamines: Non-significant interaction at therapeutic doses.
• Hormonal contraceptives: No known significant interaction.
• Common antibiotics: No known significant interaction (check with your physician for unusual antibiotic classes).

Checking Your Medications

For any medication not listed here, two resources are useful:

• TripSit Factsheets (tripsit.me) — maintains a community drug interaction database with harm reduction ratings
• Your prescribing physician — increasingly, physicians familiar with the psychedelic research literature can provide informed guidance; honest disclosure is increasingly feasible as cultural awareness grows

When in doubt, disclose everything to your facilitator and treat the unknown as a reason to proceed cautiously or consult a physician before proceeding.